(See: Drugs in American Society, 5th, 6th, 7th, 8th, and 9th editions, Erich Goode, McGraw-Hill, 1999/2005/2008/2012/2014. Chapters 1/9/10 and Drugs, Society, and Human Behavior, Ray and Ksir, Mosby, 1999. Chapter 15 (8th ed.) Statistics are gathered from the various surveys discussed, especially: Substance Abuse and Mental Health Services Administration, Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.
(Hey, don't stare at this too long!)
WWW Links
LSD-25 (this .zip file is a program to download (it will need to be unzipped!) that will give you a taste of the experience! Contact viehland@umr.edu for more information.
In addition to ergotamine and dihydroergotamine which are used in the treatment of migraines, the ergot alkaloid methylergonovine is an obstetric agent used to induce labor and to control excessive uterine bleeding. (I believe these are it’s main uses; I’m a psychiatrist so that’s not the usual end of the body that I treat.) Also, if I’m not mistaken, Hydergine (ergoloid mesylate) is also a related compound believed by some to improve cognitive ability.
The ergot preparations used in migraine therapy are potent vasoconstrictors and are metabolized in the liver by a specific subset (3A) of metabolic enzymes (known as the cytochrome P450 system). Among the antiretroviral protease inhibitors, ritonavir and indinavir are particularly potent inhibitors of the cytochrome P450 3A subset (among others). I have run across 3 case reports in which migraine treatment with ergotamine resulted in severe systemic vasoconstriction when co-administered with indinavir or ritonavir. According to the PDR, "ergotamine overdose [may] include the following: numbness, tingling, pain, and cyanosis of the extremities associated with diminished or absent peripheral pulses; respiratory depression; an increase and/or decrease in blood pressure, usually in that order; confusion, delirium, convulsions, and coma; and/or some degree of nausea, vomiting, and abdominal pain." For dyhydroergotamine the maximum recommended dose is no more than 4mg administered intranasally over the course of 7 days (in 0.5mg doses) and for ergotamine no more than 10mg (in 1mg doses) over the course of a week. Overt ergotism is rare but apparently may be precipitated by the inhibition of hepatic metabolism of these 2 drugs.
I have found no references to adverse reactions to Hydergine or methylergonovine in combination protease inhibitors or other cytochome P450 inhibitors (two common examples being nefazodone and erythromycin). Additionally there are no reports of adverse reactions to LSD in individuals taking cyp3A inhibitors. Appologies for the confusion regarding which drugs I was referring to in the phrase "these agents" near the end of my previous post.
David Gillenwater, M.D. dgillen@emory.edu
Emory University School of Medicine
Department of Psychiatry and Behavioral Health
HIV/AIDS Clinical Research Training Program
LSD's Long, Strange Trip (NY Times Retro Report 5/17/16: http://nyti.ms/23TmwIW)
(transcript)
http://www.nytimes.com/video/us/100000004406557/lsds-long-strange-trip.html
. LSD has a way of "doing that!"
"It permits you to travel backwards and forward in time, to enter other planes of existence. Even (as the Indians say), to know God..."
DrugsText Information on DMT
"...what I saw. Stars, delicate floating films of color, then an abrupt rush of countless points of white light swept across my field of view, as if the unseen millions of the Milky Way were to flow in a sparkling river before my eyes..."
(Photo from Erowid: http://www.erowid.org/)
See also: Ketamine ("Special K," "Vitamin K"): Effects
And:
Latter two seem to reflect use patterns and subcultural controls. As use has remained consistent, perhaps even slight increase; problems associated with use have decreased.
1967 | 1969 | 1972 | 1979 |
1% | 4% | 5% | maybe 20-25% (18-25 year olds) |
2013 | Hallucinogens | LSD |
Lifetime | 15.1% | 9.4% |
Past Year | 1.7% | .4% |
Past Month | .5% | .1% |
NSDUH 2003-2013, 12 years of age and older (percentages)
03 life | 04 life | 09 life | 12 life | 13 life | 03 year | 04 year | 09 year | 12 year | 13 year | 03 month | 04 month | 09 month | 12 month | 13 month | |
Hallucinogens | 14.5 | 14.3 | 14.8 |
14.6 |
15.1 |
1.7 | 1.6 | 1.8 |
1.7 |
1.7 |
.4 | .4 |
.5 |
.4 |
.5 |
LSD | 10.3 | 9.7 | 9.4 |
9.1 |
9.4 |
.2 | .2 | .3 |
.4 |
.4 |
.1 | .1 |
.1 |
.1 |
.1 |
PCP | 3 | 2.8 | 2.5 |
2.5 |
2.5 |
.1 | .1 | .0 |
.0 |
0 |
.0 | .0 |
.0 |
.0 |
0 |
Ecstasy | 4.6 | 4.6 | 5.7 |
6.2 |
6.8 |
.9 | .8 | 1.1 |
1.0 |
1.0 |
.2 | .2 |
.3 |
.2 |
.3 |
CNS Stimulants: Xanthines, Amphetamine, Nicotine, and Cocaine
URL: http://www.umsl.edu/~keelr/180/hallucin.html
Owner: Robert O. Keel rok@umsl.edu
References and Credits for this Page of Notes
Last Updated: Tuesday, November 10, 2020 10:22 AM